利奈唑胺治疗老年重症肺炎疗效和安全性分析.docVIP

利奈唑胺治疗老年重症肺炎疗效和安全性分析 　　[摘要] 目的 探讨老年重症肺炎患者采取利奈唑胺治疗的疗效与安全性。 方法 抽取我院2012年2月～2015年3月接诊的老年重症肺炎患者78例进行研究，随机分为两组，对照组38例采取万古霉素治疗，研究组40例采取利奈唑胺治疗。观察记录两组患者临床效果、死亡率及不良反应发生率，以及体温恢复正常时间、痰液颜色改变时间、肺部炎症明显吸收（50%）时间，并对比分析。 结果 研究组临床总有效率为82.50%（33/80），对照组则为52.63%（20/38），研究组显著高于对照组，差异有统计学意义（P0.05）；研究组不良反应发生率显著低于对照组，差异有统计学意义（P50%）时间均明显低于对照组，差异有统计学意义（P0.05），但研究组稍短。结论 老年重症肺炎患者采取利奈唑胺治疗可取得不错的效果，疗效明确，可明显缩短症状恢复正常时间，安全性高，值得借鉴。 　　[关键词] 老年；重症肺炎；利奈唑胺；疗效；安全性 　　[中图分类号] R563.1 [文献标识码] B [文章编号] 2095-0616（2016）01-91-04 　　[Abstract] Objective To study the effect and safety of linezolid in the treatment of severe pneumonia in senile patients. Methods Selected 78 senile patients with severe pneumonia from February 2012 to March 2015，who were received and treated in our hospital，were selected as the research objections and were randomly divided into two groups，38 cases in control group were treated with vancomycin，and 40 cases in study group were treated with linezolid.To observe and record the clinical effect，the mortality，the incidence of adverse reactions， the time of temperature returned to normal，the change time of sputum color，and the significant absorption（50%）time of pulmonary inflammation， and to comparative analyze. Results The clinical total effective rate in study group82.50%（33/80）was obviously higher than which in control group52.63%（20/38）（P0.05）.The incidence of adverse reactions study group was significantly lower than the control group，the difference was statistically significant（P50%）time of pulmonary inflammation in study group were significantly lower than which in control group， the differences were statically significant（P0.05），which in study group was a little shorter. Conclusion Linezolid in the treatment of severe pneumonia in senile patients has obtained better effect， has definite therapeutic effect， could curtail the time of symptoms returned to normal， has high safety， is worthy of reference. 　　[Key words] Gerontism；Severe pneumonia；Linezolid；Effect；Safety 　　重症肺炎属于临床比较棘手